{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:04:34Z","timestamp":1790190274320,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ijantimicag.2019.08.001","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T19:23:15Z","timestamp":1565032995000},"page":"592-600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trial"],"prefix":"10.1016","volume":"54","author":[{"given":"Ricardo Sobhie","family":"Diaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iart Luca","family":"Shytaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila B.","family":"Giron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Obermaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Ermelindo","family":"della Libera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Galinskas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Janini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele","family":"Gosuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo Abr\u00e3o","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cecilia","family":"Sucupira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Maricato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Fackler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Lusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0001","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ijantimicag.2018.09.018","article-title":"Antibacterial and antivirulence activities of auranofin against Clostridium difficile","volume":"53","author":"AbdelKhalek","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0002","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijantimicag.2015.12.016","article-title":"Repurposing auranofin for the treatment of cutaneous staphylococcal infections","volume":"47","author":"Thangamani","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0003","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ijantimicag.2016.09.020","article-title":"Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against trichomonads in vitro and in vivo","volume":"48","author":"Hopper","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0004","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1124\/mi.8.3.1","article-title":"A brief history of potable gold","volume":"8","author":"Norton","year":"2008","journal-title":"Mol Interv"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fcimb.2017.00004","article-title":"Repurposing approach identifies auranofin with broad spectrum antifungal activity that targets Mia40-Erv1 pathway","volume":"7","author":"Thangamani","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0006","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.antiviral.2017.04.014","article-title":"Host oxidative folding pathways offer novel anti-chikungunya virus drug targets with broad spectrum potential","volume":"143","author":"Langsjoen","year":"2017","journal-title":"Antiviral Res"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0007","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nm.1972","article-title":"HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation","volume":"15","author":"Chomont","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0008","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1172\/JCI86047","article-title":"Recent developments in the effort to cure HIV infection: going beyond N\u202f=\u202f1","volume":"126","author":"Siliciano","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0009","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/COH.0000000000000230","article-title":"Residual inflammation and viral reservoirs: alliance against an HIV cure","volume":"11","author":"Massanella","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0010","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1172\/JCI80564","article-title":"The role of HIV integration in viral persistence: no more whistling past the proviral graveyard","volume":"126","author":"Maldarelli","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0011","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12981-016-0114-y","article-title":"Stem cell transplantation in strategies for curing HIV\/AIDS","volume":"13","author":"H\u00fctter","year":"2016","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0012","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","article-title":"HIV-1 remission following CCR5\u039432\/\u039432 haematopoietic stem-cell transplantation","volume":"568","author":"Gupta","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0013","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation","volume":"360","author":"H\u00fctter","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0014","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/QAD.0b013e328347bd77","article-title":"Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension","volume":"25","author":"Lewis","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0015","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1006\/cimm.1993.1275","article-title":"The interaction of auranofin and buthionine sulfoximine blocks activation of human peripheral T lymphocytes","volume":"152","author":"Vint","year":"1993","journal-title":"Cell Immunol"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0016","doi-asserted-by":"crossref","first-page":"7521","DOI":"10.1128\/JVI.00396-15","article-title":"Two-year follow-up of macaques developing intermittent control of the human immunodeficiency virus homolog simian immunodeficiency virus SIVmac251 in the chronic phase of infection","volume":"89","author":"Shytaj","year":"2015","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0017","doi-asserted-by":"crossref","first-page":"e944","DOI":"10.1038\/cddis.2013.473","article-title":"A candidate anti-HIV reservoir compound, auranofin, exerts a selective \u2018anti-memory\u2019 effect by exploiting the baseline oxidative status of lymphocytes","volume":"4","author":"Chirullo","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0018","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S2055-6640(20)30310-1","article-title":"Highlights from the 22nd International AIDS Conference (AIDS 2018), 22\u201327 July 2018, Amsterdam, the Netherlands","volume":"4","author":"Psomas","year":"2018","journal-title":"J Virus Erad"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0019","doi-asserted-by":"crossref","first-page":"e718","DOI":"10.1038\/cddis.2013.248","article-title":"Altering cell death pathways as an approach to cure HIV infection","volume":"4","author":"Badley","year":"2013","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0020","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jat.3410","article-title":"Developmental toxicity of auranofin in zebrafish embryos","volume":"37","author":"Gao","year":"2017","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0021","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/ard.42.5.566","article-title":"Gold levels produced by treatment with auranofin and sodium aurothiomalate","volume":"42","author":"Lewis","year":"1983","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0022","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nm.2111","article-title":"HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects","volume":"16","author":"Buz\u00f3n","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0023","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1128\/JVI.80.4.1939-1948.2006","article-title":"Human immunodeficiency virus type 1 incorporated with fusion proteins consisting of integrase and the designed polydactyl zinc finger protein E2C can bias integration of viral DNA into a predetermined chromosomal region in human cells","volume":"80","author":"Tan","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0024","doi-asserted-by":"crossref","first-page":"12385","DOI":"10.1128\/JVI.00609-14","article-title":"Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies","volume":"88","author":"Vandergeeten","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0000000000000917","article-title":"Cell surface downregulation of NK cell ligands by patient-derived HIV-1 Vpu and Nef alleles","volume":"72","author":"Galaski","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0026","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/1471-2105-14-255","article-title":"A multiple-alignment based primer design algorithm for genetically highly variable DNA targets","volume":"14","author":"Brodin","year":"2013","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0027","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/bioinformatics\/btu832","article-title":"PrimerDesign-M: a multiple-alignment based multiple-primer design tool for walking across variable genomes","volume":"31","author":"Yoon","year":"2015","journal-title":"Bioinformatics"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0028","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1089\/aid.2016.0230","article-title":"Genetic diversity of HIV-1 gene vif among treatment-naive Brazilians","volume":"33","author":"Villanova","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0029","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.virol.2012.08.048","article-title":"The increasing prevalence of HIV-1 subtype C in Southern Brazil and its dispersion through the continent","volume":"435","author":"Gr\u00e4f","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0030","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1089\/aid.2006.22.1206","article-title":"Genomic diversity in the regulatory nef gene sequences in Indian isolates of HIV type 1: emergence of a distinct subclade and predicted implications","volume":"22","author":"Kumar","year":"2006","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0031","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1128\/JVI.02161-08","article-title":"Differentially stimulated CD4+ T cells display altered human immunodeficiency virus infection kinetics: implications for the efficacy of antiviral agents","volume":"83","author":"Vatakis","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0032","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1471-2148-10-8","article-title":"BLAST-EXPLORER helps you building datasets for phylogenetic analysis","volume":"10","author":"Dereeper","year":"2010","journal-title":"BMC Evol Biol"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0033","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ebiom.2016.04.039","article-title":"LEDGIN-mediated inhibition of integrase-LEDGF\/p75 interaction reduces reactivation of residual latent HIV","volume":"8","author":"Vranckx","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000533","article-title":"Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy","volume":"5","author":"Rong","year":"2009","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1039\/C6CC07970A","article-title":"Au(iii) compounds as HIV nucleocapsid protein (NCp7)\u2013nucleic acid antagonists","volume":"53","author":"Spell","year":"2017","journal-title":"Chem Commun"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0036","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003174","article-title":"Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies","volume":"9","author":"Eriksson","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0037","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/CMR.00015-16","article-title":"Total HIV-1 DNA, a marker of viral reservoir dynamics with clinical implications","volume":"29","author":"Avettand-F\u00e8no\u00ebl","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0038","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.1254194","article-title":"HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells","volume":"345","author":"Maldarelli","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0039","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.1256304","article-title":"HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection","volume":"345","author":"Wagner","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0040","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1073\/pnas.1522675113","article-title":"Clonally expanded CD4+ T cells can produce infectious HIV-1 in vivo","volume":"113","author":"Simonetti","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0041","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/s41467-019-08431-7","article-title":"Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion","volume":"10","author":"Pinzone","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0042","doi-asserted-by":"crossref","first-page":"E8958","DOI":"10.1073\/pnas.1802028115","article-title":"Phylogenetic approach to recover integration dates of latent HIV sequences within-host","volume":"115","author":"Jones","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0043","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12977-018-0395-4","article-title":"HIV evolution and diversity in ART-treated patients","volume":"15","author":"van Zyl","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0044","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.18889","article-title":"Establishment and stability of the latent HIV-1 DNA reservoir","volume":"5","author":"Brodin","year":"2016","journal-title":"Elife"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002506","article-title":"Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection","volume":"8","author":"Evering","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0046","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1128\/JVI.00591-06","article-title":"Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells","volume":"80","author":"Bailey","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004010","article-title":"Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy","volume":"10","author":"Kearney","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0048","doi-asserted-by":"crossref","first-page":"E4987","DOI":"10.1073\/pnas.1308313110","article-title":"The HIV-1 reservoir in eight patients on long-term suppressive antiretroviral therapy is stable with few genetic changes over time","volume":"110","author":"Josefsson","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0049","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1128\/JVI.01985-12","article-title":"An increasing proportion of monotypic HIV-1 DNA sequences during antiretroviral treatment suggests proliferation of HIV-infected cells","volume":"87","author":"Wagner","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0050","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.4156","article-title":"Defective proviruses rapidly accumulate during acute HIV-1 infection","volume":"22","author":"Bruner","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0051","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/imr.12079","article-title":"HIV-associated chronic immune activation","volume":"254","author":"Paiardini","year":"2013","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0052","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.4049\/jimmunol.169.6.3400","article-title":"CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load","volume":"169","author":"Sousa","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0053","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.it.2006.09.006","article-title":"Bystander T cell activation\u2014implications for HIV infection and other diseases","volume":"27","author":"Bangs","year":"2006","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0054","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002774","article-title":"A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model","volume":"8","author":"Shytaj","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0055","doi-asserted-by":"crossref","first-page":"e27864","DOI":"10.1371\/journal.pone.0027864","article-title":"Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected","volume":"6","author":"Guti\u00e9rrez","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0056","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S2055-6640(20)30262-4","article-title":"Careful consideration when responding to new data: dolutegravir and pregnancy","volume":"4","author":"Foster","year":"2018","journal-title":"J Virus Erad"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0057","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0140-6736(12)60821-6","article-title":"Global epidemiology of HIV infection in men who have sex with men","volume":"380","author":"Beyrer","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0058","doi-asserted-by":"crossref","first-page":"13475","DOI":"10.1073\/pnas.1406663111","article-title":"Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1","volume":"111","author":"Hill","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0059","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005000","article-title":"HIV reactivation from latency after treatment interruption occurs on average every 5\u20138 days\u2014implications for HIV remission","volume":"11","author":"Pinkevych","year":"2015","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0060","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1089\/aid.2017.0036","article-title":"Evidence of noncompetent HIV after ex vivo purging among ART-suppressed individuals","volume":"33","author":"Samer","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0061","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1038\/s41598-017-04160-3","article-title":"Anti-proliferative therapy for HIV cure: a compound interest approach","volume":"7","author":"Reeves","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2019.08.001_bib0062","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1172\/JCI85339","article-title":"Dual targeting of the thioredoxin and glutathione systems in cancer and HIV","volume":"126","author":"Benhar","year":"2016","journal-title":"J Clin Invest"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919302122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919302122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:33:10Z","timestamp":1760376790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919302122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0924857919302122"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.08.001","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potential impact of the antirheumatic agent auranofin on proviral HIV-1 DNA in individuals under intensified antiretroviral therapy: Results from a randomised clinical trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}